Document:

Plea Agreement

 Exhibit 10.57C 
 Form Date 5/06 
 GRK:grk             
 F.#2005RO697 
 UNITED STATES DISTRICT COURT 
 EASTERN DISTRICT OF NEW YORK 
  

					
	- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -X	 	
			
	 UNITED STATES OF AMERICA
	 		 	PLEA AGREEMENT
			
	 —against—
	 		 	07 CR 531 (ENV)
			
	ORPHAN MEDICAL, INC.,	 		 	
			
	 Defendant.
	 		 	
		
	- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -X	 	

 Pursuant to Rule 11 of the Federal Rules of Criminal Procedure, the United States Attorney’s
Office for the Eastern District of New York (the “Office”) and ORPHAN MEDICAL, INC. (the “defendant”) agree to the following: 
 1. The defendant will waive indictment and plead guilty to an information to be filed in this district charging a violation 21 U.S.C. §§ 331(a) and 333(a)(2). The count carries the following statutory penalties: 
  

	 	a.	Maximum fine: $500,000 or twice the pecuniary gain or loss, whichever is greater. 

 (18 U.S.C. § 3571(c)(3) and (d)). 
  

	 	b.	Restitution: $12,262,078. 

 (18 U.S.C.
§§ 3663 and 3663A). 
  

	 	c.	$400 special assessment. 

 (18 U.S.C.
§ 3013). 
  

	 	d.	Other penalties: mandatory exclusion from participation in federal health care programs. 

 2. The defendant understands that although imposition of a sentence in accordance with the United States
Sentencing Guidelines (the “Guidelines”) is not mandatory, the Guidelines are advisory and the Court is required to consider any applicable Guidelines provisions as well as other factors enumerated in 18 U.S.C. § 3553(a) to arrive at
an appropriate sentence in this case. The Office will advise the Court and the Probation Department of information relevant to sentencing, including criminal activity engaged in by the defendant, and such information may be used by the Court in
determining the defendant’s sentence. The Office estimates the recommended fine range is $28,500,000 to $57,000,000, which is predicated on the following calculation pursuant to the Guidelines effective November 1, 2006: 
 Base Fine 
  

			
	 Base offense level:
	  	6
	 (U.S.S.G. §§ 2B1.1(a)(2) and 8C2.4(a)(1))
	  	
		
	 Loss of more than $7,000,000:
	  	+ 20
	 (U.S.S.G. §§ 2B1.1(b)(1)(K) and 8C2.4(a)(1))
	  	
		
	 Offense involved more than 50 victims:
	  	+ 4
	 (U.S.S.G. §§ 2B1.1(b)(2)(B) and 8C2.4(a)(1))
	  	
		
	 Offense involved conscious or reckless risk of death or serious bodily injury:
	  	+ 2
	 (U.S.S.G. §§ 2B1.1(b)(12)(A) and 8C2.4(a)(1))
	  	
		
	 Defendant derived more than $1 million in gross receipts from one or more financial institutions:
	  	+ 2
	 (U.S.S.G. §§ 2B1.1(b)(12)(A) and 8C2.4(a)(1))
	  	

  

 2 

			
		
	 Adjusted offense level:
	  	34
		
	 Base fine: $28,500,000
	  	
	 (U.S.S.G. § 8C2.4(d))
	  	

 Culpability Score 
  

			
	 Base culpability score:
	  	5
	 (U.S.S.G. § 8C2.5(a))
	  	
		
	 Organization had 50 or more employees and substantial authority personnel condoned or were willfully ignorant of offense:
	  	+ 2
	 (U.S.S.G. § 8C2.5(b)(4))
	  	
		
	 Organization fully cooperated in investigation and demonstrated acceptance of responsibility:
	  	- 2
	 (U.S.S.G. § 8C2.5(g)(2))
	  	
	 Total culpability score:
	  	5

 Minimum and Maximum Fine Range 
  

				
	 Minimum fine
	  		
	 $28,500,000 base fine x 1.00 multiplier:
	  	$	28,500,000
	 (U.S.S.G. §§ 8C2.6 and 8C2.7(a))
	  		
		
	 Maximum fine
	  		
	 $28,500,000 base fine x 2.00 multiplier:
	  	$	57,000,000
	 (U.S.S.G. §§ 8C2.6 and 8C2.7(b))
	  		

 The defendant does not stipulate to this estimate of the recommended fine range. The government represents and for
purposes of this agreement the defendant does not object that, pursuant to U.S.S.G. §8C2.4(a) and 18 U.S.C. § 3571(d), the loss from this offense for criminal sentencing purposes is $12,262,078. The defendant and the government both
acknowledge that the loss figure cannot be determined with precision and that the loss figure of $12,262,078 for criminal sentencing purposes is an estimate. 
  

 3 

 3. The government and the defendant agree that, pursuant to U.S.S.G. § 8C3.3(b), the defendant is
not able and, even with the use of a reasonable installment schedule, is not likely to become able to pay the minimum fine required by U.S.S.G. § 8C2.7. Therefore, the government and the defendant agree, pursuant to Fed. R. Crim. P.
11(c)(1)(C), that the following sentence is the appropriate disposition of the Information: 
  

	 	a.	Restitution in the amount of $12,262,078, to be paid after sentencing in installments pursuant to the following schedule: 

  

				
	 July 20, 2007
	  	$	613,104
	 January 15, 2008
	  	$	1,226,208
	 January 15, 2009
	  	$	1,532,760
	 January 15, 2010
	  	$	1,839,312
	 January 15, 2011
	  	$	1,839,312
	 January 15, 2012
	  	$	5,211,382

  

	 	b.	A criminal fine in the amount of $5 million, to be paid after sentencing in installments pursuant to the following schedule: 

  

				
	 July 20, 2007
	  	$	250,000
	 January 15, 2008
	  	$	500,000
	 January 15, 2009
	  	$	625,000
	 January 15, 2010
	  	$	750,000
	 January 15, 2011
	  	$	750,000
	 January 15, 2012
	  	$	2,125,000

  

	 	c.	a mandatory special assessment of $400 pursuant to 18 U.S.C. § 3013. 

 4. The Guidelines estimate set forth in paragraph 2 is not binding on the Office, the Probation Department or the Court. 
  

 4 

 If the Guidelines offense level advocated by the Office, or determined by the Probation Department or the Court, is
different from the estimate, the defendant will not be entitled to withdraw the plea. The defendant’s plea will be tendered pursuant to Fed. R. Crim P. 11(c)(1)(C). The defendant cannot withdraw its plea of guilty unless the sentencing judge
rejects this agreement or fails to impose the stipulated sentence referenced above. If the sentencing judge rejects this agreement, this agreement shall be null and void at the option of either the government or the defendant. The defendant intends
to seek a sentencing by the Court immediately following the Rule 11 plea hearing and in the absence of a Presentence Report in this case. The defendant understands that the decision whether to proceed immediately following the plea hearing with the
sentencing proceeding, and to do so without a Presentence Report, is exclusively that of the Court. 
 5. The defendant will not file an
appeal or otherwise challenge by petition pursuant to 28 U.S.C. § 2255 or any other provision the conviction or sentence in the event that the Court imposes a total fine of $57 million or less. This waiver is binding without regard to the
sentencing analysis used by the Court. The defendant waives all defenses based on the statute of limitations and venue with respect to any prosecution that is not time-barred on the date that this agreement is signed in the event that (a) the
defendant’s conviction is later vacated for 
  

 5 

 
any reason, (b) the defendant violates this agreement, or (c) the defendant’s plea is later withdrawn. The defendant waives any right to
additional disclosure from the government in connection with the guilty plea. The defendant agrees that with respect to all charges referred to in paragraphs 1 and 5(a) it is not a “prevailing party” within the meaning of the “Hyde
Amendment,” 18 U.S.C. § 3006A note, and will not file any claim under that law. The defendant agrees to pay the special assessment by check payable to the Clerk of the Court at or before sentencing. 
 6. The Office agrees that: 
  

	 	a.	no further criminal charges will be brought against the defendant for its participation in criminal activity involving a scheme to market the drug Xyrem for medical indications that
were not approved by the U.S. Food and Drug Administration and to secure insurance reimbursement for such unapproved medical indications, all from the period of in or about 2003 through in or about 2006, it being understood that this agreement does
not bar the use of such conduct as a predicate act or as the basis for a sentencing enhancement in a subsequent prosecution including, but not limited to, a prosecution pursuant to 18 U.S.C. §§ 1961 et seq. 

and, based upon information now known to the Office, it will 
  

	 	b.	advocate the agreed sentence set forth in paragraph 3 before the Court. 

 If information relevant to sentencing, as determined by the Office, becomes known to the Office after the date of this agreement, the Office will not be bound by paragraph 5(b). Should it be judged by the Office that the defendant has
violated 

  

 6 

 
any provision of this agreement, the defendant will not be released from its plea of guilty but this Office will be released from its obligations under this
agreement, including but not limited to the provisions of paragraph 5 (a) and (b). 
 7. This agreement is binding upon the Attorney
General of the United States, the Department of Justice, and all United States Attorneys on the matters as set forth in paragraph 6 but cannot and does not bind the Tax Division of the U.S. Department of Justice or the Internal Revenue Service of
the U.S. Department of the Treasury. The defendant also understands that this agreement does not bind any state or local prosecuting authority. 
 8. No promises, agreements or conditions have been entered into by the parties other than those set forth in this agreement and none will be entered into unless memorialized in writing and signed by all parties. This agreement supersedes
all 

  

 7 

 
prior promises, agreements or conditions between the parties. To become effective, this agreement must be signed by all signatories listed below. 

 

			
	Dated:	 	Brooklyn, New York
		 	July 13, 2007

  

			
	ROSLYNN R. MAUSKOPF
	United States Attorney
	Eastern District of New York
		
	By:	 	 /s/ Geoffrey R. Kaiser

		 	Geoffrey R. Kaiser
		 	Assistant United States Attorney

  

	
	Approved by:
	
	 /s/ Richard T. Faughnan

	Richard T. Faughnan
	Supervising Assistant U.S. Attorney

 I have read the entire agreement and discussed it with my attorney. I understand all of its terms and am
entering into it knowingly and voluntarily. 
  

	
	 /s/ Robert M. Myers

	Robert M. Myers
	President, ORPHAN MEDICAL, INC.
	

  

	
	Approved by:
	
	 /s/ J. Sedwick Sollers III

	J. Sedwick Sollers III
	Mark Jensen
	Counsel to Defendant

  

 8Corporate Integrity Agreement

 Exhibit 10.57D 
 CORPORATE INTEGRITY AGREEMENT 
 BETWEEN THE 
 OFFICE OF INSPECTOR GENERAL 
 OF THE 
 DEPARTMENT
OF HEALTH AND HUMAN SERVICES 
 AND

 JAZZ PHARMACEUTICALS, INC. 
  

	I.	PREAMBLE 

 Jazz Pharmaceuticals, Inc. (Jazz) hereby enters into this Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) of the United States Department of Health and Human Services (HHS) to promote
compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) (Federal health care program requirements) and the statutes,
regulations, and written directives of the Food and Drug Administration (FDA) (FDA requirements). Contemporaneously with this CIA, Jazz is entering into a Settlement Agreement with the United States. Jazz will also enter into settlement agreements
with various states and Jazz’s agreement to this CIA is a condition precedent to those settlement agreements. 
 Prior to the Effective
Date, Jazz established a comprehensive compliance program (Compliance Program), which includes a corporate Compliance Officer and compliance committee, a code of conduct for all employees, written policies and procedures, educational and training
initiatives, review and disciplinary procedures, a confidential disclosure program, and internal review procedures designed, as represented by Jazz, to promote compliance with applicable laws and the promotion of high ethical standards. 

Jazz shall continue its Compliance Program throughout the term of this CIA and shall do so in accordance with the terms set forth below. Jazz may
modify its compliance measures as appropriate, but, at a minimum, Jazz shall ensure that during the term of this CIA, it shall comply with the integrity obligations set forth herein. 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 1 

	II.	TERM AND SCOPE OF THE CIA 

 A. The period of the compliance obligations assumed by Jazz under this CIA shall be five years from the effective date of this CIA, unless otherwise
specified. The effective date shall be the date on which the final signatory of this CIA executes this CIA (Effective Date). Each one-year period, beginning with the one-year period following July 1, 2007 shall be referred to as a
“Reporting Period.” 
 B. Sections VII, IX, X, and XI shall expire no later than 120 days after OIG=s receipt of:
(1) Jazz’s final Annual Report; or (2) any additional materials submitted by Jazz pursuant to OIG=s request, whichever is later. 
 C. The scope of this CIA shall be governed by the following definitions: 
 1. “Covered Persons” includes: 
 a. all owners who are natural persons (other than shareholders who: (1) have an ownership interest of less than 5%; and (2) acquired the
ownership interest through public trading), officers, directors, and employees of Jazz; and 
 b. all contractors, subcontractors, agents,
and other persons who perform Product Services Related Functions (as defined below in Section II.C.2) on behalf of Jazz. 
 Notwithstanding
the above, the term “Covered Persons” does not include part-time or per diem employees, contractors, subcontractors, agents, and other persons who are not reasonably expected to work more than 160 hours per year, except that any such
individuals shall become “Covered Persons” at the point when they work more than 160 hours during the calendar year. 
 2.
“Relevant Covered Persons” includes all Covered Persons of Jazz whose job responsibilities relate to: i) the sales, marketing, or promotion of Jazz’s products; ii) research and development (except preclinical researchers and clinical
investigators); iii) the distribution of Jazz’s products (except those Covered Persons with no sales, marketing, or promotional related responsibilities); or iv) the provision of information about or services relating to Jazz products
(collectively “Product Services Related Functions.”). 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 2 

 3. An “Educational or Informational Activity” shall mean any continuing medical education
(CME), disease awareness, or other scientific, educational or professional program, meeting, or event, including, but not limited to, sponsorship of booths or activities at medical conferences or symposia. 
  

	III.	CORPORATE INTEGRITY OBLIGATIONS  

 Jazz shall maintain a Compliance Program that includes the following elements: 
 A. Compliance Officer and Committee. 
 1. Compliance Officer. Within 120 days after the Effective Date, Jazz shall appoint an individual to serve as its compliance officer (Compliance Officer), and Jazz shall maintain a Compliance Officer for the term of the CIA. The
Compliance Officer shall be responsible for developing and implementing policies, procedures, and practices designed to ensure compliance with the requirements set forth in this CIA and with Federal health care program and FDA requirements. The
Compliance Officer is and shall continue to be a member of the management of Jazz, shall report to the Chief Executive Officer, shall make periodic (at least quarterly) reports regarding compliance matters directly to the Board of Directors of Jazz,
and shall be authorized to report on such matters to the Board of Directors (or a designated committee or subcommittee of the Board) at any time. The Compliance Officer shall not be or be subordinate to the General Counsel or Chief Financial
Officer. The Compliance Officer shall be responsible for monitoring the day-to-day compliance activities engaged in by Jazz as well as for any reporting obligations created under this CIA. 
 Jazz shall report to OIG, in writing, any changes in the identity or position description of the Compliance Officer, or any actions or changes that would
affect the Compliance Officer’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change. 
 2. Compliance Committee. Prior to the Effective Date, Jazz established a Compliance Committee, and Jazz shall maintain the Compliance Committee during the term of this CIA. The Compliance Committee shall,
at a minimum, consist of the General Counsel; the Compliance Officer; the Senior Vice President, Development; the 

  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 3 

 
Chief Financial Officer; the Vice President, Sales; and the Vice President, Marketing and New Product Planning. As represented by Jazz, the
aforementioned individuals are the members of management necessary to meet the requirements of this CIA. The Compliance Officer shall chair the Compliance Committee and the Committee shall support the Compliance Officer in fulfilling his/her
responsibilities (e.g., shall assist in the analysis of Jazz’s risk areas and shall oversee monitoring of internal and external audits and investigations). 
 Jazz shall report to OIG, in writing, any changes in the composition of the Compliance Committee, or any actions or changes that would affect the Compliance Committee’s ability to perform the duties necessary to
meet the obligations in this CIA, within 15 days after such a change. 
 B. Written Standards. 
 1. Code of Conduct. To the extent not already accomplished, within 90 days after the Effective Date, Jazz shall develop, implement, and distribute
a written Code of Conduct to all Covered Persons. Jazz shall make the promotion of, and adherence to, the Code of Conduct an element in evaluating the performance of all employees. The Code of Conduct shall, at a minimum, set forth: 
 a. Jazz’s commitment to full compliance with all Federal health care program and FDA requirements, including its commitment to comply with all
requirements relating to Product Services Related Functions; 
 b. Jazz’s requirement that all of its Covered Persons shall be expected
to comply with all Federal health care program and FDA requirements and with Jazz’s own Policies and Procedures as implemented pursuant to Section III.B (including the requirements of this CIA); 
 c. the requirement that all of Jazz’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual
designated by Jazz, suspected violations of any Federal health care program or FDA requirements or of Jazz’s own Policies and Procedures; 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 4 

 d. the possible consequences to both Jazz and Covered Persons of failure to comply with Federal health
care program or FDA requirements and with Jazz’s own Policies and Procedures and the failure to report such noncompliance; and 
 e. the
right of all individuals to use the Disclosure Program described in Section III.E, and Jazz’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. 
 Within 90 days after the Effective Date, each Covered Person shall certify, in writing, that he or she has received, read, understood, and shall abide by
Jazz’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 90 days after the Effective Date, whichever is later.

 Jazz shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions based
on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in writing, that he or she has received, read, understood, and shall abide by the revised Code of
Conduct within 30 days after the distribution of the revised Code of Conduct. 
 2. Policies and Procedures. To the extent not already
accomplished, within 90 days after the Effective Date, Jazz shall implement written Policies and Procedures regarding the operation of Jazz’s compliance program and its compliance with Federal health care program and FDA requirements. At a
minimum, the Policies and Procedures shall address: 
 a. the subjects relating to the Code of Conduct identified in Section III.B.1;

 b. selling, marketing, and promoting of Jazz products in compliance with all applicable Federal health care program requirements,
including, but not limited to, the Federal anti-kickback statute, codified at 42 U.S.C. § 1320a-7b(b) and the False Claims Act codified at 31 U.S.C. § 3729-3733; 
 c. selling, marketing, promoting, advertising, and disseminating 

  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 5 

 
information about Jazz’s products in compliance with all applicable FDA requirements, including procedures governing the response to requests for
information about off-label uses; 
 d. compensation (including salaries and bonuses) for Covered Persons that are designed to ensure that
financial incentives do not inappropriately motivate sales and marketing personnel to engage in the improper promotion, sales, and marketing of Jazz’s products; 
 e. disciplinary policies and procedures for violations of Jazz’s Policies and Procedures, including those policies relating to Federal health care program and FDA requirements; 
 f. the manner in which Jazz receives and response to requests for information about off-label uses of Jazz’s products; the form and content of
information disseminated by Jazz in response to such requests; and the internal review process for the information disseminated. 
 The
Policies and Procedures shall include a requirement that Jazz develop one or more databases to track requests for information about Jazz’ products that are made to Jazz’ Medical Information department. Collectively these databases shall be
referred to as the “Inquiries Database.” The Inquiries Database shall includes the following items of information for each unique inquiry (Inquiry) received for information about Jazz’s products: 1) date of Inquiry; 2) form of Inquiry
(e.g., fax, phone, etc.); 3) name of the requesting health care professional (HCP); 4) nature and topic of request (including exact language of the Inquiry if made in writing); 5) an evaluation of whether the Inquiry relates to information
about an off-label indication for the product; 6) nature/form of the response from Jazz (including a record of the materials provided to the HCP in response to the request); 7) the name of the Jazz representative who called on or interacted with the
HCP; and 8) the status and findings of any follow-up review conducted by Jazz in situations in which it appears that the Inquiry may have related to improper off-label promotion; 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 6 

 g. speaker programs, advisory board programs, focus group programs, and all other consultant
arrangements. These policies shall be designed to ensure that the consultant arrangements and related events are used for legitimate and lawful purposes in accordance with applicable Federal health care program and FDA requirements. The policies
shall include requirements about the uses, content, and circumstances of such arrangements and events; 
 h. funding of, or participation in,
any Educational or Informational Activity as defined in Section II.C.3 above (e.g., third party educational grants or sponsorship for CME or other third-party educational programs or events). These Policies and Procedures shall be designed to
ensure that Jazz’s funding and/or sponsorship of such programs satisfies all applicable Federal health care program and FDA requirements related to the sponsorship of any Educational or Informational Activity. 
 The Policies and Procedures shall require: 1) the disclosure of Jazz’s financial support of the Educational or Informational Activity and any
financial relationships with faculty, speakers, or organizers at such Educational or Informational Activity; 2) that the Educational or Informational Activity have an educational focus; 3) that the Educational or Informational Activity be
independent; 4) that the Educational or Informational Activity be non-promotional in tone/nature; and 5) that the information provided at the Educational or Informational Activity be fair, balanced, accurate and not misleading; 
 i. funding of charitable grants or sponsorships in a manner that is designed to ensure that Jazz’s funding complies with all applicable Federal
health care program requirements and FDA requirements; and 
 j. sponsorship or funding of research activities (including clinical trials,
market research, or authorship of articles or other publications) by Jazz in a manner that is designed to ensure that Jazz’s funding or sponsorship of such activities complies with all applicable Federal health care program and FDA
requirements. In addition, such Policies and Procedures shall ensure that sales and marketing activities are separate from clinical trial enrollment. 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 7 

 Within 90 days after the Effective Date, the relevant portions of the Policies and Procedures shall be
distributed to all individuals whose job functions relate to those Policies and Procedures. Appropriate and knowledgeable staff shall be available to explain the Policies and Procedures. 
 At least annually (and more frequently, if appropriate), Jazz shall assess and update, as necessary, the Policies and Procedures. Within 30 days after
the effective date of any revisions, the relevant portions of any such revised Policies and Procedures shall be distributed to all individuals whose job functions relate to those Policies and Procedures. 
 C. Training and Education. 
 1.
General Training. Within 120 days after the Effective Date, Jazz shall provide at least one hour of General Training to each Covered Person. This training, at a minimum, shall explain Jazz’s: 
  

	 	a.	CIA requirements; 

  

	 	b.	Jazz’s Compliance Program (including the Code of Conduct and the Policies and Procedures as they pertain to general compliance issues); and 

  

	 	c.	in general, the proper methods of promoting, marketing, selling, conducting research (including clinical trials), and disseminating information about Jazz’s products in
accordance with Federal health care program and FDA requirements. 

 To the extent that General Training provided to Covered
Persons during the 90 days immediately prior to the execution of this CIA satisfies the requirements of Sections III.C.1.b-c, above, the OIG shall credit the training toward the training requirements set forth in this Section III.C.1 for the first
Reporting Period. Jazz may satisfy its remaining General Training obligation for those Covered Persons who received training as described above by notifying the Covered Persons in writing of the fact that Jazz entered a CIA and notifying them of
Jazz’s requirements and obligations under the CIA. 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 8 

 New Covered Persons shall receive the General Training described above within 30 days after becoming a
Covered Person or within 120 days after the Effective Date, whichever is later. After receiving the initial General Training described above, each Covered Person shall receive at least one hour of General Training in each subsequent Reporting
Period. 
 2. Specific Training. Within 120 days after the Effective Date, each Relevant Covered Person shall receive at least two
hours of Specific Training in addition to the General Training required above. Each Relevant Covered Person shall also receive at least one additional hour of Specific Training during the first Reporting Period. This Specific Training shall include
a discussion of: 
 a. all Federal health care program requirements relevant to Product Services Related Functions, including, but not
limited to, the requirements of the Federal anti-kickback statute; the Civil Monetary Penalties Law; the civil False Claims Act; and the Medicaid Drug Rebate statute; 
 b. all applicable FDA requirements relevant to Product Services Related Functions, including but not limited to, the requirements of the Federal Food, Drug, and Cosmetic Act and FDA regulations; 
 c. the personal obligation of each Relevant Covered Person involved in Product Services Related Functions to comply with all applicable legal
requirements; 
 d. the legal sanctions for violations of the Federal health care program requirements or FDA requirements relating to
Product Services Related Functions; and 
 e. examples of proper and improper practices relating to Product Services Related Functions.

 To the extent that Specific Training provided to Relevant Covered Persons during the 90 days immediately prior to the execution of this
CIA satisfies the requirements of this Section III.C.2, the OIG shall credit the training toward the Specific Training requirements for the first Reporting Period. 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 9 

 New Relevant Covered Persons shall receive this training within 30 days after the beginning of their
employment or becoming Relevant Covered Persons, or within 120 days after the Effective Date, whichever is later. A Jazz employee who has completed the Specific Training shall review a new Relevant Covered Person’s work, to the extent that the
work relates to Product Services Related Functions, until such time as the new Relevant Covered Person completes his or her Specific Training. 
 After receiving the initial Specific Training described in this Section, each Relevant Covered Person shall receive at least two hours of Specific Training in each subsequent Reporting Period. 
 In addition to the Specific Training obligations set forth in this Section III.2.C, as part of its Compliance Program, Jazz provides additional regular
periodic training to Relevant Covered Persons on the topics outlined above in this Section III.C.2. This training shall be known as the “Periodic Compliance Training”. Jazz shall continue to provide Periodic Compliance Training to Relevant
Covered Persons during the term of the CIA. Jazz shall include a description of the Periodic Compliance Training as part of its Annual Reports, but Jazz shall not be required to formally track the Periodic Compliance Training for each individual
Relevant Covered Person. 
 3. Certification. Each individual who is required to attend training shall certify, in writing, or in
electronic form, if applicable, that he or she has received the required training. The certification shall specify the type of training received and the date received. The Compliance Officer (or designee) shall retain the certifications, along with
all course materials. These shall be made available to OIG, upon request. 
 4. Qualifications of Trainer. Persons providing the
training shall be knowledgeable about the subject area, including the applicable Federal health care program and FDA requirements. 
 5.
Update of Training. Jazz shall review the training annually, and, where appropriate, update the training to reflect changes in applicable Federal health care program or FDA requirements, any issues discovered during internal audits or any of
the IRO Reviews, and any other relevant information. 
 6. Computer-based Training. Jazz may provide the training required under this
CIA through appropriate computer-based training approaches. If Jazz chooses to provide computer-based training, it shall make available appropriately qualified and knowledgeable staff or trainers to answer questions or provide additional information
to the individuals receiving such training. 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 10 

 D. Review Procedures. 
 1. General Description. 
 a.
Engagement of Independent Review Organization. Within 90 days after the Effective Date, Jazz shall engage an entity (or entities), such as an accounting, auditing, or consulting firm (hereinafter “Independent Review Organization” or
“IRO”), to perform a Promotional and Product Services Engagement. 
 Each IRO engaged by Jazz shall have expertise in the
requirements of the requirements of the Federal health care program and FDA requirements applicable to the Promotional and Product Services Engagement. Each IRO shall assess, along with Jazz, whether it can perform the IRO review in a professionally
independent and objective fashion, as appropriate to the nature of the engagement, taking into account any other business relationships or other engagements that may exist. The applicable requirements relating to the IRO are outlined in Appendix A
to this CIA, which is incorporated by reference. 
 b. Description and Frequency of Reviews. The Promotional and Product Services
Engagement shall consist of two components – a systems review (the Promotional and Product Services Systems Review) and a transactions review (Promotional and Product Services Transactions Review), as described more fully in Appendix B to this
CIA, which is incorporated by reference. 
 The Promotional and Product Services Transactions Review shall be performed annually and shall
cover each of the Reporting Periods. The IRO(s) shall perform all components of each of these annual Reviews. 
 The IRO shall perform the
Promotional and Product Services Systems Review for the first Reporting Period as outlined in Appendix B. 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 11 

 c. Retention of Records. The IRO and Jazz shall retain and make available to OIG, upon request,
all work papers, supporting documentation, correspondence, and draft reports (those exchanged between the IRO and Jazz) related to the reviews. 
 2. Review Reports. The IRO shall prepare a report (Report) based upon each Promotional and Product Services Transaction Review and Promotional and Product Services Systems Review performed. Information to be included in each Report
is described in Appendix B. 
 3. Validation Review. In the event OIG has reason to believe that: (a) any of the IRO Reviews
fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Review in question complied with the
requirements of the CIA and/or the findings or Review results are inaccurate (Validation Review). Jazz shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted
as part of Jazz’s final Annual Report shall be initiated no later than one year after Jazz’s final submission (as described in Section II) is received by OIG. 
 Prior to initiating a Validation Review, OIG shall notify Jazz of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Jazz may
request a meeting with OIG to: (a) discuss the results of any Review submissions or findings; (b) present any additional information to clarify the results of the Review in question or to correct the inaccuracy of the Review; and/or
(c) propose alternatives to the proposed Validation Review. Jazz agrees to provide any additional information as may be requested by OIG under this Section in an expedited manner. OIG will attempt in good faith to resolve any IRO Review issues
with Jazz prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG. 
 4. Independence and Objectivity Certification. The IRO shall include in its report(s) to Jazz a certification or sworn affidavit that it has
evaluated its professional independence and objectivity, as appropriate to the nature of the engagement, with regard to the applicable Review and that it has concluded that it is, in fact, independent and objective. 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 12 

 E. Disclosure Program. 
 Prior to the Effective Date, Jazz established a Disclosure Program that includes mechanisms (a toll-free compliance telephone line and an e-mail
mechanism) to enable individuals to disclose, to the Compliance Officer or some other person who is not in the disclosing individual’s chain of command, any identified issues or questions associated with Jazz’s policies, conduct,
practices, or procedures with respect to any Federal health care program or FDA requirement believed by the individual to be a potential violation of criminal, civil, or administrative law. Jazz shall continue the Disclosure Program during the term
of this CIA. Jazz shall appropriately publicize the existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the information in prominent common areas). 
 The Disclosure Program shall emphasize a nonretribution, nonretaliation policy, and shall include a reporting mechanism for anonymous communications for
which appropriate confidentiality shall be maintained. Upon receipt of a disclosure, the Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Compliance Officer (or designee) shall make a
preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is
sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Jazz shall conduct an internal review of the
allegations set forth in the disclosure and ensure that proper follow-up is conducted. 
 The Compliance Officer (or designee) shall maintain
a disclosure log, which shall include a record and summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews. The disclosure log
shall be made available to OIG upon request. 
 F. Ineligible Persons. 
 1. Definitions. For purposes of this CIA: 
 a. an “Ineligible Person” shall include an individual or entity who: 
 i. is currently excluded, debarred, suspended, or
otherwise ineligible to participate in the Federal health care programs or in Federal procurement or nonprocurement programs; or 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 13 

 ii. has been convicted of a criminal offense that falls within the ambit of 42 U.S.C. § 1320a-7(a),
but has not yet been excluded, debarred, suspended, or otherwise declared ineligible. 
 b. “Exclusion Lists” include: 

i. the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://www.oig.hhs.gov); and 
 ii. the General Services Administration’s List of Parties Excluded from Federal Programs (available through the Internet at
http://www.epls.gov). 
 c. “Screened Persons” include prospective and current owners (other than shareholders who:
(1) have an ownership interest of less than 5%; and (2) acquired the ownership interest through public trading), officers, directors, employees, contractors, and agents of Jazz. 
 2. Screening Requirements. Jazz shall ensure that all Screened Persons are not Ineligible Persons, by implementing the following screening
requirements. 
 a. Jazz shall screen all Screened Persons against the Exclusion Lists prior to engaging their services and, as part of the
hiring or contracting process, shall require such Screened Persons to disclose whether they are Ineligible Persons. 
 b. Jazz shall screen
all Screened Persons against the Exclusion Lists within 90 days after the Effective Date and on an annual basis thereafter. 
 c. Jazz shall
implement a policy requiring all Screened Persons to disclose immediately any debarment, exclusion, suspension, or other event that makes that person an Ineligible Person. 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 14 

 Nothing in this Section affects the responsibility of (or liability for) Jazz to refrain from billing (if
applicable) Federal health care programs for items or services furnished, ordered, or prescribed by an Ineligible Person. Jazz understands that items or services furnished by excluded persons are not payable by Federal health care programs and that
Jazz may be liable for overpayments and/or criminal, civil, and administrative sanctions for employing or contracting with an excluded person regardless of whether Jazz meets the requirements of Section III.F. 
 3. Removal Requirement. If Jazz has actual notice that a Screened Person has become an Ineligible Person, Jazz shall remove such Screened Person
from responsibility for, or involvement with, Jazz’s business operations related to the Federal health care programs and shall remove such Screened Person from any position for which the Screened Person’s compensation or the items or
services furnished, ordered, or prescribed by the Screened Person are paid in whole or part, directly or indirectly, by Federal health care programs or otherwise with Federal funds at least until such time as the Screened Person is reinstated into
participation in the Federal health care programs. 
 4. Pending Charges and Proposed Exclusions. If Jazz has actual notice that a
Screened Person is charged with a criminal offense that falls within the ambit of 42 U.S.C. §§ 1320a-7(a), 1320a-7(b)(1)-(3), or is proposed for exclusion during the Screened Person’s employment or contract term, Jazz shall take all
appropriate actions to ensure that the responsibilities of that Screened Person have not and shall not adversely affect any claims submitted to any Federal health care program. 
 G. Notification of Government Investigation or Legal Proceedings. 
 Within 30 days after discovery, Jazz shall notify OIG, in writing, of any ongoing investigation or legal proceeding known to Jazz conducted or brought by a governmental entity or its agents involving an allegation
that Jazz has committed a crime or has engaged in fraudulent activities. This notification shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal
proceeding. Jazz shall also provide written notice to OIG within 30 days after the resolution of the matter, and shall provide OIG with a description of the findings and/or results of the investigation or proceedings, if any. 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 15 

 H. Reporting. 
 1. Reportable Events. 
 a. Definition of Reportable Event. For purposes of this CIA, a
“Reportable Event” means anything that involves: 
 i. a matter that a reasonable person would consider a probable violation of
criminal, civil, or administrative laws applicable to any Federal health care program and/or applicable to any FDA requirements relating to the promotion of prescription drugs for which penalties or exclusion may be authorized; or 
 iii. the filing of a bankruptcy petition by Jazz. 
 A Reportable Event may be the result of an isolated event or a series of occurrences. 
 b. Reporting of Reportable Events.
If Jazz determines (after a reasonable opportunity to conduct an appropriate review or investigation of the allegations) through any means that there is a Reportable Event, Jazz shall notify OIG, in writing, within 30 days after making the
determination that the Reportable Event exists. The report to OIG shall include the following information: 
 i. a complete description of
the Reportable Event, including the relevant facts, persons involved, and legal and Federal health care program and/or FDA authorities implicated; 
 iii. a description of Jazz’s actions taken to correct the Reportable Event; and 
 iv. any further steps Jazz plans to take to
address the Reportable Event and prevent it from recurring. 
 v. If the Reportable Event involves the filing of a bankruptcy petition, the
report to the OIG shall include documentation of the filing and a description of any Federal health care program and/or FDA authorities implicated. 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 16 

 I. Notification of Communications with FDA. 
 Within 30 days after the date of any written report, correspondence, or communication from Jazz to the FDA that materially discusses Jazz’s or a
Covered Person’s unlawful or improper promotion of Jazz’s products (including any improper dissemination of information about off-label indications), Jazz shall provide a copy of the report, correspondence, or communication to the OIG.
Jazz shall also provide written notice to the OIG within 30 days after the resolution of any such disclosed off-label matter, and shall provide the OIG with a description of the findings and/or results of the matter, if any. 
 J. Review of Records Reflecting the Content of Detailing Sessions. 
 Each Reporting Period beginning with the second Reporting Period, Jazz shall obtain non-Jazz records (e.g., Verbatims or similar records) generated by an independent entity (Survey Entity) reflecting the
purported content and subject matter of detailing interactions between sales representatives and HCPs for up to three Jazz products (Covered Products) to be selected by OIG as described below. In order to satisfy its obligations under this Section
III.J, Jazz may propose that it obtain an alternative type of survey record (e.g., message recall studies) rather than the records of the detailing sessions. The OIG will consider Jazz’s proposal, and, after considering Jazz’s
proposal, shall, in its discretion, identify the type of survey records to be obtained. Prior to the beginning of the second Reporting Period, the OIG will determine (after input from Jazz) whether the Field Sales Force Monitoring Program outlined
below in Section III.L and the accompanying documentation required under that Section are sufficient to justify waiving the requirement to obtain and review records reflecting the content of detailing sessions as set forth in this Section III.J.

 For each Covered Product, Jazz shall contract with the Survey Entity to conduct inquiries into the content and subject matter of the
detailing interactions. The OIG shall select and notify the Survey Entity of a one-week period within every other quarter of the Reporting Period for which the surveys shall be conducted, beginning in the second full quarter after the Effective
Date. For each Covered Product, Jazz shall obtain records reflecting the purported content and subject matter of detailing sessions during the identified week in all regions across the United States. 
 Jazz shall review the records obtained and shall identify any instances in which the records appear to indicate that Covered Persons may have discussed
and/or disseminated information about off-label uses of the Covered Products. Jazz shall make findings based on its review (Off-Label Findings) and shall take any responsive action it deems necessary. If necessary for purposes of its review, Jazz
shall endeavor to gather 

  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 17 

 
additional factual information about the circumstances relating to any Off-Label Findings. As part of each Annual Report, Jazz shall provide the OIG with
copies of the underlying records of the detailing interactions, a copy of Jazz’s Off-Label Findings, and a description of the action(s), if any, Jazz took in response to the Off-Label Findings. 
 Prior to the start of the second Reporting Period and every Reporting Period thereafter, based on the information provided by Jazz and other information
known to it, and after consultation with Jazz, the OIG shall select up to three Jazz products to be reviewed under this Section III.J. These products shall be known as the “Covered Products”, and the OIG shall notify Jazz of the Covered
Products for each applicable Reporting Period. The parties have already identified the Covered Products for the first Reporting Period. 
 K.
Monitoring and Review of Medical Information Requests. 
 Jazz’s Policies and Procedures address the selling, marketing,
promoting, and dissemination of information about Jazz’s products in compliance with all applicable Federal health care program and FDA requirements and the procedures governing the manner in which sales personnel are to respond to requests for
information about non-FDA approved uses (e.g., off-label uses). Among other things, Jazz’s Policies and Procedures provide that its sales personnel may not directly or indirectly solicit, encourage, or promote any Jazz product for
off-label uses. In addition, the Policies and Procedures provide that inquiries about off-label uses are to be directed to Jazz’s Medical Information department. Jazz’s Medical Information department responds to requests for medical and
scientific information from physicians, patients, and others (Inquiries). 
 Jazz records and documents all Inquiries in the Inquiries
Database. The Inquiries Database contains the information identified in Section III.B.2.f above for each Inquiry. On at least a monthly basis, Jazz generates and shall continue to generate reports of the Inquiries received and the responses to the
Inquiries. These reports shall continue to be forwarded to the Compliance Officer or other compliance personnel. The Compliance Officer (or designee) shall continue to review these reports to assess whether the information contained in the report
suggests that improper promotion may have occurred in connection with any Inquiry(ies). 
 If the Compliance Officer, in consultation with
other appropriate Jazz personnel, suspects that improper promotion may have occurred in connection with one or more Inquiries, the Compliance Officer shall undertake a follow-up review of the Inquiry (Off-Label Review). The Compliance Officer shall
make specific findings based 

  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 18 

 
on the Off-Label Review, and take any responsive action (including disciplinary action and reporting of the conduct (including disclosing Reportable Events
pursuant to Section III.H above, if applicable) deemed necessary and appropriate. On at least a semi-annual basis, the Compliance Officer shall review the Medical Information department’s policies and procedures relating to the handling of
Inquiries concerning off-label uses of Jazz’s products and shall provide a report on the results of such review to the Compliance Committee. 
 Jazz shall maintain a record of the steps undertaken during each Off-Label Review, including a general description of the process by which the Compliance Officer conducted the Off-Label Review, the types of records reviewed and the
identities of individuals interviewed. Any findings made during the Off-Label Review and any corrective action taken shall be recorded in the files of the Compliance Department and summarized in the Annual Reports. Jazz shall make its records
relating to its reviews of Inquiries and any Off-Label Reviews available to the OIG upon request 
 L. Jazz’s Field Sales Force
Monitoring Program. 
 Jazz compliance and legal personnel conduct at least two types of reviews of the activities of Jazz’s field
sales force. First, Jazz conducts periodic and regular reviews of the call notes recorded by its field sales force (Call Note Reviews). Second, Jazz conducts compliance-focused ride-alongs with its field sales force personnel (Ride-Along Reviews).
These activities shall collectively be referred to as the “Field Sales Force Monitoring Program”, and Jazz shall continue the Field Sales Force Monitoring Program as set forth below during the term of the CIA. 
 In connection with the Call Note Review, in the first quarter of each Reporting Period, Jazz shall conduct an audit of a sample of call notes prepared by
field sales representatives. The sample will consist of all call notes prepared by at least 20 percent of Jazz’s field sales representatives during two different months of the preceding Reporting Period. If the number of field sales
representatives for the applicable Reporting Period exceeds 100 employees, Jazz shall notify the OIG of this fact and the OIG will determine, after input from Jazz, whether to reduce the percentage of field sales representatives whose call notes are
included as part of the sample. The field sales representatives and the months to be sampled will be selected randomly by Jazz’s compliance department. After the sample of call notes has been selected, the Compliance Officer (or designee) shall
review the call notes to assess whether the information contained in the call notes suggests that any improper promotion may have occurred. 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 19 

 In connection with the Ride Along Reviews, the Compliance Officer or other trained personnel from the
Compliance, legal, or regulatory affairs departments shall directly observe all meetings between Jazz field sales representatives and HCPs during a full work day for at least 10 of Jazz’s field sales representatives during each Reporting
Period. The field sales representatives observed shall be located throughout the country and shall be supervised by different sales managers. If the number of field sales representatives for the applicable Reporting Period exceeds 100 employees,
Jazz shall notify the OIG of this fact and the OIG will determine, after input from Jazz, whether to increase the number of field sales representatives who are observed during Ride Along Reviews and, if so, the number of field sales representatives
to be observed. Jazz shall continue these Ride Along Reviews during the term of this CIA as outlined below. 
 After the completion of each
observation day conducted as part of the Ride Along Reviews, compliance personnel shall complete an Observation Report which, for each interaction observed between a sales representatives and an HCP or his/her office staff, shall include the
following information: 1) the identity of the sales representative and the compliance or other personnel conducting the observation; 2) the date and duration of the observation; 3) the Jazz product(s) promoted during the observation; 4) assessments
about the interaction between the sales representative and each HCP visited; and 5) an identification and description of any potential improper promotion of any Jazz product(s). The Observation Reports shall be forwarded to the Compliance Officer
for review. 
 If the Compliance Officer, in consultation with other appropriate Jazz personnel, suspects that improper promotion may have
occurred in connection with either the Call Note Review or any Ride Along Review, the Compliance Officer shall undertake a follow-up review (Compliance Review). The Compliance Officer shall make specific findings based on the Compliance Review, and
take any responsive action (including disciplinary action and reporting of the conduct (including disclosing Reportable Events pursuant to Section III.H above, if applicable) deemed necessary and appropriate. Jazz shall retain records relating to
the Call Note Reviews, the Ride Along Reviews, and any Compliance Reviews, and shall make such records available to the OIG upon request. A description of the Call Note Reviews, the Ride Along Reviews, any Compliance Reviews, and any findings made
during the Compliance Reviews shall be summarized in the Annual Reports. 
  

	IV.	NEW BUSINESS UNITS OR LOCATIONS 

 In the event that, after the Effective Date, Jazz changes locations or sells, closes, purchases, or establishes a new business unit or location related to
Product Services Related Functions, Jazz shall notify OIG of this fact as soon as possible, but no later than 

  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 20 

 
within 30 days after the date of change of location, sale, closure, purchase, or establishment. This notification shall include the address of the new
business unit or location, phone number, fax number, any Federal health care program provider identification number and/or supplier number, and any corresponding contractor’s name and address that has issued each Federal health care program
provider number. Each new business unit or location shall be subject to all the requirements of this CIA. 
  

	V.	IMPLEMENTATION AND ANNUAL REPORTS 

 A. Implementation Report. Within 150 days after the Effective Date, Jazz shall submit a written report to OIG summarizing the status of its
implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 
 1. the
name, address, phone number, and position description of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 
 2. the names and positions of the members of the Compliance Committee required by Section III.A; 
 3. a copy of Jazz’s Code of Conduct required by Section III.B.1; 
 4. a copy of all Policies and Procedures required by Section III.B.2; 
 5. the number of individuals
required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be
available to OIG, upon request); 
 6. the following information regarding each type of training required by Section III.C: 
 a. a description of such training, including a summary of the topics covered, the length of sessions and a schedule of training sessions; 
 b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. 
 A copy of all training materials and the documentation supporting this information shall be available to OIG, upon request. 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 21 

 7. a description of the Disclosure Program required by Section III.E; 
 8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; and (c) a
summary and description of any and all current and prior engagements and agreements between Jazz and the IRO; and the proposed start and completion dates of each Review; 
 9. a certification from the IRO regarding its professional independence and objectivity with respect to Jazz; 
 10. a description of the process by which Jazz fulfills the requirements of Section III.F regarding Ineligible Persons; 
 11. the
name, title, and responsibilities of any person who is determined to be an Ineligible Person under Section III.F; and the actions taken in response to the screening and removal obligations set forth in Section III.F; 
 12. a list of all of Jazz’s locations (including locations and mailing addresses); the corresponding name under which each location is doing
business; the corresponding phone numbers and fax numbers; each location’s Federal health care program provider and/or supplier number(s) (if applicable); and the name and address of each Federal health care program contractor to which Jazz
currently submits claims (if applicable); 
 13. a description of Jazz’s corporate structure, including identification of any parent and
sister companies, subsidiaries, and their respective lines of business; and 
 14. the certifications required by Section V.C. 
 B. Annual Reports. Jazz shall submit to OIG annually a report with respect to the status of, and findings regarding, Jazz’s compliance
activities for each of the five Reporting Periods (Annual Report). 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 22 

 Each Annual Report shall include, at a minimum: 
 1. any change in the identity, position description, or other noncompliance job responsibilities of the Compliance Officer and any change in the
membership of the Compliance Committee described in Section III.A; 
 2. a summary of any significant changes or amendments to the Policies
and Procedures required by Section III.B and the reasons for such changes (e.g., change in contractor policy); 
 3. the number of
individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information
shall be available to OIG, upon request); 
 4. the following information regarding each type of training required by Section III.C:

 a. a description of such training, including a summary of the topics covered, the length of sessions and a schedule of training sessions;

 b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions.

 A copy of all training materials and the documentation supporting this information shall be available to OIG, upon request. 
 5. a complete copy of all reports prepared pursuant to Section III.D, along with a copy of the IRO’s engagement letter (if applicable); 

6. Jazz’s response and corrective action plan(s) related to any issues raised by the reports prepared pursuant to Section III.D; 
 7. a summary and description of any and all current and prior engagements and agreements between Jazz and the IRO, if different from what was submitted
as part of the Implementation Report; 
 8. a certification from the IRO regarding its professional independence and objectivity with respect
to Jazz; 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 23 

 9. a summary of all internal reviews, audits, or analyses related to Speaker Programs/Teleconferences or
any other Product Services Related Functions (including, at a minimum, the objective of the review, audit, or analysis; the protocol or methodology for the review, audit, or analysis; and the results of the review, audit, or analysis) and any
corrective action plans developed in response to such reviews, audits, or analyses; 
 10. a summary of Reportable Events (as defined in
Section III.H) identified during the Reporting Period and the status of any corrective and preventative action relating to all such Reportable Events; 
 11. a summary of the disclosures in the disclosure log required by Section III.E that relate to Federal health care programs or to FDA requirements; 
 12. any changes to the process by which Jazz fulfills the requirements of Section III.F regarding Ineligible Persons; 
 13. the name, title, and responsibilities of any person who is determined to be an Ineligible Person under Section III.F; and the actions taken by Jazz
in response to the screening and removal obligations set forth in Section III.F; 
 14. a summary describing any ongoing investigation or
legal proceeding required to have been reported pursuant to Section III.G. The summary shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding;

 15. a summary describing any ongoing communication with the FDA required to have been reported pursuant to Section III.I. The summary
shall include a description of the matter, and the status of such matter; 
 16. a copy of all information required by Section III.J;

 17. a list and description of all actively promoted Jazz products; and information about the estimated relative usage (e.g., the
percentage) of those products for off-label purposes; 
 18. a summary describing the findings resulting from any Off-Label Reviews, as
required by Section III.K; 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 24 

 19. a copy of all information required by Section III.L; 
 20. a description of all changes to the most recently provided list of Jazz’s locations (including addresses) as required by Section V.A.12; the
corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Federal health care program provider or supplier number(s) (if applicable), and the name and address of each
Federal health care program contractor to which Jazz currently submits claims (if applicable); and 
 21. the certifications required by
Section V.C. 
 The first Annual Report shall be received by OIG no later than 60 days after the end of the first Reporting Period.
Subsequent Annual Reports shall be received by OIG no later than the anniversary date of the due date of the first Annual Report. 
 C.
Certifications. The Implementation Report and Annual Reports shall include a certification by the Compliance Officer that: 
 1. to the
best of his or her knowledge, except as otherwise described in the applicable Report, Jazz is in compliance with all of the requirements of this CIA; 
 2. he or she has reviewed the Report and has made reasonable inquiry regarding its content and believes that the information in the Report is accurate and truthful; 
 3. if applicable, Jazz has complied with its obligations under the Settlement Agreement: (a) not to resubmit to any Federal health care program
payors any previously denied claims related to the Covered Conduct addressed in the Settlement Agreement, and not to appeal any such denials of claims; (b) not to charge to or otherwise seek payment from federal or state payors for unallowable
costs (as defined in the Settlement Agreement); and (c) to identify and adjust any past charges or claims for unallowable costs; and 
 4. Jazz’: 1) Policies and Procedures as referenced in Section III.B.2 above; 2) templates for the standardized contracts and other similar documents; 3) training materials used for purposes of Section III.C, above; and 4) promotional
or educational materials containing claims or information about Jazz’s products have been reviewed by competent legal counsel and have been found to be in compliance with the requirements of the Federal anti-kickback statute, the Prescription
Drug Marketing Act, and other 

  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 25 

 
applicable laws. If the applicable legal requirements have not changed, after the initial review of the documents listed above, only material changes to the
documents must be reviewed by competent legal counsel. The certification shall include a description of the document(s) reviewed and approximately when the review was completed. The documentation supporting this certification shall be available to
OIG, upon request. 
 D. Designation of Information. Jazz shall clearly identify any portions of its submissions that it believes are
trade secrets, or information that is commercial or financial and privileged or confidential, and therefore potentially exempt from disclosure under the Freedom of Information Act (FOIA), 5 U.S.C. § 552. Jazz shall refrain from identifying any
information as exempt from disclosure if that information does not meet the criteria for exemption from disclosure under FOIA. 
  

	VI.	NOTIFICATIONS AND SUBMISSION OF REPORTS

 Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be
submitted to the following entities: 
  

			
	OIG:	  	
		  	 Administrative and Civil Remedies Branch
 Office of
Counsel to the Inspector General
 Office of Inspector General
 U.S. Department of Health and Human Services
 Cohen Building, Room 5527
 330 Independence Avenue, S.W.
 Washington, DC 20201
 Telephone: 202.619.2078
 Facsimile: 202.205.0604

		
	Jazz:	  	 Compliance Officer
 Jazz Pharmaceuticals,
Inc.
 3180 Porter Drive
 Palo Alto, CA 94304
 Telephone: 650.496.2777
 Facsimile: 650.396.3781

 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail,
overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 26 

	VII.	OIG INSPECTION, AUDIT, AND REVIEW RIGHTS

 In addition to any other rights OIG may have by statute, regulation, or contract, OIG or its duly authorized
representative(s) may examine or request copies of Jazz’s books, records, and other documents and supporting materials and/or conduct on-site reviews of any of Jazz’s locations for the purpose of verifying and evaluating:
(a) Jazz’s compliance with the terms of this CIA; and (b) Jazz’s compliance with the requirements of the Federal health care programs in which it participates and with applicable FDA requirements. The documentation described
above shall be made available by Jazz to OIG or its duly authorized representative(s) at all reasonable times for inspection, audit, or reproduction. Furthermore, for purposes of this provision, OIG or its duly authorized representative(s) may
interview any of Jazz’s employees, contractors, or agents who consent to be interviewed at the individual’s place of business during normal business hours or at such other place and time as may be mutually agreed upon between the
individual and OIG. Jazz shall assist OIG or its duly authorized representative(s) in contacting and arranging interviews with such individuals upon OIG’s request. Jazz’s employees may elect to be interviewed with or without a
representative of Jazz present. 
  

	VIII.	DOCUMENT AND RECORD RETENTION 

 Jazz shall maintain for inspection all documents and records relating to reimbursement from the Federal health care programs, or to compliance with this
CIA, for six years (or longer if otherwise required by law) from the Effective Date. 
  

	IX.	DISCLOSURES 

 Consistent with HHS’s FOIA procedures, set forth in 45 C.F.R. Part 5, OIG shall make a reasonable effort to notify Jazz prior to any release by OIG of information submitted by Jazz pursuant to its obligations under this CIA and
identified upon submission by Jazz as trade secrets, or information that is commercial or financial and privileged or confidential, under the FOIA rules. With respect to such releases, Jazz shall have the rights set forth at 45 C.F.R. §
5.65(d). 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 27 

	X.	BREACH AND DEFAULT PROVISIONS 

 Jazz is expected to fully and timely comply with all of its CIA obligations. 
 A. Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, Jazz and OIG hereby agree that failure to comply
with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 
 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Jazz fails to establish
and implement any of the following obligations as described in Section III: 
  

	 	a.	a Compliance Officer; 

  

	 	b.	a Compliance Committee; 

  

	 	c.	a written Code of Conduct; 

  

	 	d.	written Policies and Procedures; 

  

	 	e.	the training of Covered Persons; 

  

	 	f.	a Disclosure Program; 

  

	 	g.	Ineligible Persons screening and removal requirements; 

  

	 	h.	notification of Government investigations or legal proceedings; 

  

	 	i.	notification of communications regarding off-label related matters; 

  

	 	j.	a review of records reflecting the content of detailing sessions; 

  

	 	k.	monitoring and review of Medical Information Requests; and 

  

	 	l.	the Field Sales Force Monitoring Program as described in Section III.L. 

  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 28 

 2. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation
became due) for each day Jazz fails to engage an IRO, as required in Section III.D and Appendices A and B. 
 3. A Stipulated Penalty of
$2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Jazz fails to submit the Implementation Report or any Annual Reports to OIG in accordance with the requirements of Section V by the deadlines for
submission. 
 4. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each
day Jazz fails to submit the annual Report associated with any of the Reviews in accordance with the requirements of Section III.D and Appendix B. 
 5. A Stipulated Penalty of $1,500 for each day Jazz fails to grant access as required in Section VII. (This Stipulated Penalty shall begin to accrue on the date Jazz fails to grant access.) 
 6. A Stipulated Penalty of $5,000 for each false certification submitted by or on behalf of Jazz as part of its Implementation Report, Annual Report,
additional documentation to a report (as requested by the OIG), or otherwise required by this CIA. 
 7. A Stipulated Penalty of $1,000 for
each day Jazz fails to comply fully and adequately with any obligation of this CIA. OIG shall provide notice to Jazz stating the specific grounds for its determination that Jazz has failed to comply fully and adequately with the CIA obligation(s) at
issue and steps Jazz shall take to comply with the CIA. (This Stipulated Penalty shall begin to accrue 10 days after Jazz receives this notice from OIG of the failure to comply.) A Stipulated Penalty as described in this Subsection shall not be
demanded for any violation for which OIG has sought a Stipulated Penalty under Subsections 1-6 of this Section. 
 B. Timely Written
Requests for Extensions. Jazz may, in advance of the due date, submit a timely written request for an extension of time to perform any act or file any notification or report required by this CIA. Notwithstanding any other provision in this
Section, if OIG grants the timely written request with respect to an act, notification, or report, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until one day after Jazz fails to
meet the revised deadline set by 

  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 29 

 
OIG. Notwithstanding any other provision in this Section, if OIG denies such a timely written request, Stipulated Penalties for failure to perform the act or
file the notification or report shall not begin to accrue until three business days after Jazz receives OIG’s written denial of such request or the original due date, whichever is later. A “timely written request” is defined as a
request in writing received by OIG at least five business days prior to the date by which any act is due to be performed or any notification or report is due to be filed. 
 C. Payment of Stipulated Penalties. 
 1. Demand Letter. Upon a finding that Jazz has failed to
comply with any of the obligations described in Section X.A and after determining that Stipulated Penalties are appropriate, OIG shall notify Jazz of: (a) Jazz’s failure to comply; and (b) OIG’s exercise of its contractual right
to demand payment of the Stipulated Penalties (this notification is referred to as the “Demand Letter”). 
 2. Response to
Demand Letter. Within 10 days after the receipt of the Demand Letter, Jazz shall either: (a) cure the breach to OIG’s satisfaction and pay the applicable Stipulated Penalties or (b) request a hearing before an HHS administrative
law judge (ALJ) to dispute OIG’s determination of noncompliance, pursuant to the agreed upon provisions set forth below in Section X.E. In the event Jazz elects to request an ALJ hearing, the Stipulated Penalties shall continue to accrue until
Jazz cures, to OIG’s satisfaction, the alleged breach in dispute. Failure to respond to the Demand Letter in one of these two manners within the allowed time period shall be considered a material breach of this CIA and shall be grounds for
exclusion under Section X.D. 
 3. Form of Payment. Payment of the Stipulated Penalties shall be made by certified or cashier’s
check, payable to: “Secretary of the Department of Health and Human Services,” and submitted to OIG at the address set forth in Section VI. 
 4. Independence from Material Breach Determination. Except as set forth in Section X.D.1.c, these provisions for payment of Stipulated Penalties shall not affect or otherwise set a standard for OIG’s
decision that Jazz has materially breached this CIA, which decision shall be made at OIG’s discretion and shall be governed by the provisions in Section X.D, below. 
 D. Exclusion for Material Breach of this CIA. 
 1. Definition of Material Breach. A material
breach of this CIA means: 
 a. a failure by Jazz to report a Reportable Event, take corrective action, and make the appropriate refunds, as
required in Section III.H; 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 30 

 b. a repeated or flagrant violation of the obligations under this CIA, including, but not limited to,
the obligations addressed in Section X.A; 
 c. a failure to respond to a Demand Letter concerning the payment of Stipulated Penalties in
accordance with Section X.C; or 
 d. a failure to engage and use an IRO in accordance with Section III.D and Appendices A-B. 
 2. Notice of Material Breach and Intent to Exclude. The parties agree that a material breach of this CIA by Jazz constitutes an independent basis
for Jazz’s exclusion from participation in the Federal health care programs. Upon a determination by OIG that Jazz has materially breached this CIA and that exclusion is the appropriate remedy, OIG shall notify Jazz of: (a) Jazz’s
material breach; and (b) OIG’s intent to exercise its contractual right to impose exclusion (this notification is hereinafter referred to as the “Notice of Material Breach and Intent to Exclude”). 
 3. Opportunity to Cure. Jazz shall have 30 days from the date of receipt of the Notice of Material Breach and Intent to Exclude to demonstrate to
OIG’s satisfaction that: 
 a. Jazz is in compliance with the obligations of the CIA cited by OIG as being the basis for the material
breach; 
 b. the alleged material breach has been cured; or 
 c. the alleged material breach cannot be cured within the 30-day period, but that: (i) Jazz has begun to take action to cure the material breach; (ii) Jazz is pursuing such action with due diligence; and
(iii) Jazz has provided to OIG a reasonable timetable for curing the material breach. 
 4. Exclusion Letter. If, at the
conclusion of the 30-day period, Jazz fails to 

  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 31 

 
satisfy the requirements of Section X.D.3, OIG may exclude Jazz from participation in the Federal health care programs. OIG shall notify Jazz in writing of
its determination to exclude Jazz (this letter shall be referred to hereinafter as the “Exclusion Letter”). Subject to the Dispute Resolution provisions in Section X.E, below, the exclusion shall go into effect 30 days after the date of
Jazz’s receipt of the Exclusion Letter. The exclusion shall have national effect and shall also apply to all other Federal procurement and nonprocurement programs. Reinstatement to program participation is not automatic. After the end of the
period of exclusion, Jazz may apply for reinstatement by submitting a written request for reinstatement in accordance with the provisions at 42 C.F.R. §§ 1001.3001-.3004. 
 E. Dispute Resolution 
 1. Review
Rights. Upon OIG’s delivery to Jazz of its Demand Letter or of its Exclusion Letter, and as an agreed-upon contractual remedy for the resolution of disputes arising under this CIA, Jazz shall be afforded certain review rights comparable to
the ones that are provided in 42 U.S.C. § 1320a-7(f) and 42 C.F.R. Part 1005 as if they applied to the Stipulated Penalties or exclusion sought pursuant to this CIA. Specifically, OIG’s determination to demand payment of Stipulated
Penalties or to seek exclusion shall be subject to review by an HHS ALJ and, in the event of an appeal, the HHS Departmental Appeals Board (DAB), in a manner consistent with the provisions in 42 C.F.R. § 1005.2-1005.21. Notwithstanding the
language in 42 C.F.R. § 1005.2(c), the request for a hearing involving Stipulated Penalties shall be made within 10 days after receipt of the Demand Letter and the request for a hearing involving exclusion shall be made within 25 days after
receipt of the Exclusion Letter. 
 2. Stipulated Penalties Review. Notwithstanding any provision of Title 42 of the United States
Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for Stipulated Penalties under this CIA shall be: (a) whether Jazz was in full and timely compliance with the obligations of this CIA for which OIG demands
payment; and (b) the period of noncompliance. Jazz shall have the burden of proving its full and timely compliance and the steps taken to cure the noncompliance, if any. OIG shall not have the right to appeal to the DAB an adverse ALJ decision
related to Stipulated Penalties. If the ALJ agrees with OIG with regard to a finding of a breach of this CIA and orders Jazz to pay Stipulated Penalties, such Stipulated Penalties shall become due and payable 20 days after the ALJ issues such a
decision unless Jazz requests review of the ALJ decision by the DAB. If the ALJ decision is properly appealed to the DAB and the DAB upholds the determination of OIG, the Stipulated Penalties shall become due and payable 20 days after the DAB issues
its decision. 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 32 

 3. Exclusion Review. Notwithstanding any provision of Title 42 of the United States Code or Title
42 of the Code of Federal Regulations, the only issues in a proceeding for exclusion based on a material breach of this CIA shall be: 
 a.
whether Jazz was in material breach of this CIA; 
 b. whether such breach was continuing on the date of the Exclusion Letter; and

 c. whether the alleged material breach could not have been cured within the 30-day period, but that: (i) Jazz had begun to take
action to cure the material breach within that period; (ii) Jazz has pursued and is pursuing such action with due diligence; and (iii) Jazz provided to OIG within that period a reasonable timetable for curing the material breach and Jazz
has followed the timetable. 
 For purposes of the exclusion herein, exclusion shall take effect only after an ALJ decision favorable to OIG,
or, if the ALJ rules for Jazz, only after a DAB decision in favor of OIG. Jazz’s election of its contractual right to appeal to the DAB shall not abrogate OIG’s authority to exclude Jazz upon the issuance of an ALJ’s decision in favor
of OIG. If the ALJ sustains the determination of OIG and determines that exclusion is authorized, such exclusion shall take effect 20 days after the ALJ issues such a decision, notwithstanding that Jazz may request review of the ALJ decision by the
DAB. If the DAB finds in favor of OIG after an ALJ decision adverse to OIG, the exclusion shall take effect 20 days after the DAB decision. Jazz shall waive its right to any notice of such an exclusion if a decision upholding the exclusion is
rendered by the ALJ or DAB. If the DAB finds in favor of Jazz, Jazz shall be reinstated effective on the date of the original exclusion. 
 4. Finality of Decision. The review by an ALJ or DAB provided for above shall not be considered to be an appeal right arising under any statutes or regulations. Consequently, the parties to this CIA agree that the DAB’s decision
(or the ALJ’s decision if not appealed) shall be considered final for all purposes under this CIA. 
  

	XI.	EFFECTIVE AND BINDING AGREEMENT 

 Jazz and OIG agree as follows: 
 A. This CIA
shall be binding on the successors, assigns, and transferees of Jazz; 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 33 

 B. This CIA shall become final and binding on the date the final signature is obtained on the CIA;

 C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this
CIA; 
 D. The undersigned Jazz signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatory
represents that he is signing this CIA in his official capacity and that he is authorized to execute this CIA. 
 E. This CIA may be executed
in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. 
  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 34 

 ON BEHALF OF JAZZ
PHARMACEUTICALS, INC. 
  

					
	 /s/ Samuel R. Saks, M.D.
	 		 	7/13/07
	Samuel R. Saks, M.D.	 		 	DATE
	Chief Executive Officer	 		 	
	Jazz Pharmaceuticals, Inc.	 		 	

  

					
	 /s/ John T. Bentivoglio
	 		 	7/13/07
	John T. Bentivoglio	 		 	DATE
	Mark A. Jensen	 		 	
	Counsel for Jazz Pharmaceuticals, Inc.	 		 	

  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 35 

 ON BEHALF OF THE OFFICE
OF INSPECTOR GENERAL 
 OF THE DEPARTMENT
OF HEALTH AND HUMAN SERVICES 
  

					
	 /s/ Gregory E. Demske
	 		 	7/13/07
	Gregory E. Demske	 		 	DATE
	Assistant Inspector General for Legal Affairs	 		 	
	Office of Inspector General	 		 	
	U. S. Department of Health and Human Services	 		 	

  

 Corporate Integrity Agreement 
 Jazz Pharmaceuticals, Inc. 
 36 

 APPENDIX A 
 INDEPENDENT REVIEW ORGANIZATION 
 This Appendix contains the requirements relating to the Independent Review
Organization (IRO) required by Section III.D of the CIA. 
  

	A.	IRO Engagement. 

 Jazz shall engage an IRO that
possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days
after OIG receives written notice of the identity of the selected IRO, OIG will notify Jazz if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Jazz may continue to engage the IRO. 
 If Jazz engages a new IRO during the term of the CIA, this IRO shall also meet the requirements of this Appendix. If a new IRO is engaged, Jazz shall
submit the information identified in Section V.A.8 to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives written notice of the identity of the selected IRO, OIG will notify Jazz if the IRO is unacceptable. Absent
notification from OIG that the IRO is unacceptable, Jazz may continue to engage the IRO. 
  

	B.	IRO Qualifications. 

 The IRO shall: 
 1. assign individuals to conduct the Promotional and Product Services Engagement who have expertise in the Federal health care program and FDA
requirements applicable to Product Services Related Functions. The assigned individuals shall also be knowledgeable about the general requirements general requirements of the Federal health care program(s) under which Jazz products are reimbursed;

 2. assign individuals to design and select the Promotional and Product Services Engagement samples who are knowledgeable about the
appropriate statistical sampling techniques; and 
 3. have sufficient staff and resources to conduct the reviews required by the CIA on a
timely basis. 
  

	C.	IRO Responsibilities. 

 The IRO shall: 
 1. perform each Promotional and Product Services Engagement in accordance with the specific requirements of the CIA, including Appendix B to the CIA;

  

 Appendix A to CIA 
 Jazz
Pharmaceuticals, Inc. 
 Page 1 

 2. follow all applicable Federal health care program and FDA requirements in making assessments in the
Promotional and Product Services Engagement; 
 3. respond to all OIG inquires in a prompt, objective, and factual manner; and 
 4. prepare timely, clear, well-written reports that include all the information required by Appendix B. 
  

	D.	IRO Independence and Objectivity. 

 The IRO must perform the
Promotional and Product Services Engagement in a professionally independent and objective fashion, as appropriate to the nature of the engagement, taking into account any other business relationships or engagements that may exist between the IRO and
Jazz. 
  

	E.	IRO Removal/Termination. 

 1. Provider. If
Jazz terminates its IRO during the course of the engagement, Jazz must submit a notice explaining its reasons to OIG no later than 30 days after termination. Jazz must engage a new IRO in accordance with Paragraph A of this Appendix. 
 2. OIG Removal of IRO. In the event OIG has reason to believe that the IRO does not possess the qualifications described in Paragraph B, is not
independent and/or objective as set forth in Paragraph D, or has failed to carry out its responsibilities as described in Paragraph C, OIG may, at its sole discretion, require Jazz to engage a new IRO in accordance with Paragraph A of this Appendix.

 Prior to requiring Jazz to engage a new IRO, OIG shall notify Jazz of its intent to do so and provide a written explanation of why OIG
believes such a step is necessary. To resolve any concerns raised by OIG, Jazz may request a meeting with OIG to discuss any aspect of the IRO’s qualifications, independence or performance of its responsibilities and to present additional
information regarding these matters. Jazz shall provide any additional information as may be requested by OIG under this Paragraph in an expedited manner. OIG will attempt in good faith to resolve any differences regarding the IRO with Jazz prior to
requiring Jazz to terminate the IRO. However, the final determination as to whether or not to require Jazz to engage a new IRO shall be made at the sole discretion of OIG. 
  

 Appendix A to CIA 
 Jazz
Pharmaceuticals, Inc. 
 Page 2 

 Appendix B 
 Promotional and Product Services Engagement 
  

	I.	IRO Engagement, General Description  

 As
specified more fully below, Jazz shall retain an Independent Review Organization (IRO) to perform engagements to assist Jazz in assessing and evaluating its systems, processes, policies, and procedures related to Product Services Related Functions
(Promotional and Product Services Engagement). The Promotional and Product Services Engagement shall consist of two components - a systems review (the Promotional and Product Services Systems Review) and a transactions review (Promotional and
Product Services Transactions Review), as described more fully below. Jazz may engage, at its discretion, a single IRO to perform both components of the Promotional and Product Services Engagement, provided that the entity has the necessary
expertise and capabilities to perform both. As set forth below and in the CIA, Jazz shall engage an IRO to conduct the Promotional and Product Services Transactions Review for each year of the CIA. The IRO shall perform the Promotional and Product
Services Systems Review for the first Reporting Period. 
  

	II.	Promotional and Product Services Systems Review  

  

	 	A.	Description of Reviewed Policies and Procedures  

 The Promotional and Product Services Systems Review shall be a review of Jazz’s systems, processes, policies, and procedures (including the controls on those systems, processes, policies, and procedures) relating to Product Services
Related Functions. Where practical, Jazz personnel may compile documentation, schedule and organize interviews, and undertake other efforts to assist the IRO in performing the Systems Review. The IRO is not required to undertake a de novo review of
the information gathered or activities undertaken by Jazz pursuant to the preceding sentence. 
 For the first Reporting Period, the IRO
shall review Jazz’ systems, processes, policies, and procedures associated with the following (hereinafter, “Reviewed Policies and Practices”): 
  

	 	1.	Jazz’s systems, policies, processes, and procedures applicable to the manner in which the Jazz field sales force and Jazz headquarters personnel handle requests or inquiries
relating to information about off-label uses of Jazz products, and the manner in which Jazz disseminates materials relating to off-label uses of products. This review includes: 

 (i) the instructions to field sales personnel and/or headquarters personnel who receive and respond to requests for information about off-label uses and
the manner in which such personnel implement the instructions; 
  

 1 
 Appendix B to CIA 
 Jazz Pharmaceuticals, Inc. 

 (ii) the procedures for reviewing the form and content of information disseminated by headquarters
personnel (e.g. the Medical Information department); 
 (iii) Jazz’s internal review process for the information disseminated by
headquarters personnel; 
 (iv) Jazz’s systems, processes, and procedures (including its Inquiries Database described in Section
III.B.2.f of the CIA) to track requests for information about off-label uses of products and responses to those requests; 
 (v) the manner
in which Jazz collects and supports information reported in its Inquiries Database; 
 (vi) the processes and procedures by which the
Compliance Officer (and other appropriate individuals within Jazz) identify situations in which it appears that improper off-label promotion may have occurred; and 
 (vii) Jazz’s processes and procedures for investigating, documenting, resolving, and taking appropriate disciplinary action for potential situations involving off-label promotion; 
  

	 	2.	Jazz’s policies and procedures applicable to the manner and circumstances under which Medical Information personnel participate in meetings or events with physicians,
pharmacists, or other health care professionals (HCPs) (either alone or with members of the sales force) and the role of the Medical Information personnel at such meeting or events; 

  

	 	3.	Jazz’s systems, policies, processes, and procedures relating to the retention of HCPs as consultants (e.g., including as members of advisory boards, focus groups, or
clinical research project teams) or speakers. This shall include a review of: 

 (i) the criteria used to determine whether,
how many, and under what circumstances (including venue for the performance of any services) Jazz will enter contracts for such consulting or speaking arrangements; 
  

 2 
 Appendix B to CIA 
 Jazz Pharmaceuticals, Inc. 

 (ii) the processes and criteria used to identify and select HCPs with whom Jazz enters consultant,
speaker, or other contractual arrangements, including the role played by field sales personnel in the process. This includes a review of Jazz’s internal review and approval process for such contracts, and the circumstances under which there may
be exception to the process; 
 (iii) Jazz’s tracking or monitoring of services provided or the work performed by the consultants or
speakers (including the receipt of the consultant’s work product, if any); 
 (iv) Jazz’s policies and procedures related to
circumstances, if any, under which the recipient or the recipient’s agent is required to disclose the existence of the consulting or speaking arrangement in place between Jazz and the HCP; 
 (v) the uses made of work product received from consultants or speakers, if any; 
 (vi) Jazz’s processes for establishing the amounts paid to HCPs and the reasons or justifications for any differentials in the amounts paid to
different HCPs; 
 (vii) the criteria used to determine under what circumstances entertainment, recreation, travel, lodging, meals and/or
other items or reimbursements are provided to consultants or speakers, and Jazz’s processes for establishing the amounts reimbursed or the type of entertainment or recreation provided; 
 (viii) whether and in what manner Jazz tracks or monitors the prescribing habits or product use of individuals or entities with whom it enters
consulting, speakers, or other contractual arrangements, if any; and 
 (ix) the budget funding source within Jazz (e.g., department
or division) for the consulting or contractual arrangement; 
  

 3 
 Appendix B to CIA 
 Jazz Pharmaceuticals, Inc. 

	 	4.	Jazz’s systems, policies, processes, and procedures relating to funding or sponsorship of any Educational or Informational Activity. This review shall include a review of the
following items: 

 (i) the processes and procedures used to approve the funding or sponsorship of an Educational or
Informational Activity; 
 (ii) the criteria used to determine whether and under what circumstances the funding or sponsorship will be
provided; 
 (iii) the processes and criteria used to select recipients of the funding or sponsorships, including the role played by field
sales personnel in the processes (if any), and the circumstances under which there may be exceptions to the processes; 
 (iv) Jazz’s
policies and procedures related to circumstances, if any, under which the recipient or the recipient’s agent is required to disclose Jazz’s funding or sponsorship and any financial relationship Jazz may have with the recipients;

 (v) Jazz’s policies or procedures for determining and memorializing the amounts paid to recipients of the funding or sponsorship and
the purpose or justifications for the amounts paid; 
 (vi) Jazz’s policies and procedures relating to the independence of any programs
funded through the funding or the sponsorship; 
 (vii) Jazz’s policies and procedures relating to the content and promotional nature of
any programs sponsored through the funding or sponsorship; 
 (viii) whether and in what manner Jazz tracks or monitors the prescribing
habits or product use of individuals or entities receiving the funding or sponsorship, if any; and 
 (ix) the budget funding source within
Jazz (e.g., department or division) from which the funding or sponsorships are provided; 
  

 4 
 Appendix B to CIA 
 Jazz Pharmaceuticals, Inc. 

	 	5.	Jazz’s systems, policies, processes, and procedures for compensating (including with salaries and bonuses) non-Overtime Eligible employees, with regard to whether the systems,
policies, processes, and procedures are designed to ensure that financial incentives do no inappropriately motivate sales and marketing personnel to engage in the improper promotion, sales, and marketing of Jazz’s products. This shall include a
review of the bases upon which compensation is determined and the extent to which compensation is based on product performance; and 

  

	 	6.	Jazz’s systems, policies, processes, and procedures relating to the development of call plans for Jazz’s sales staff. This shall include a review of the basis upon which
physician specialties are included or excluded from the call plan based upon their potential on-label and off-label utilization of Jazz products. 

  

	 	B.	Promotional and Product Services Systems Review Report  

 The IRO shall prepare a report which, for each of the Reviewed Policies and Practices identified in Section II.A above, shall include the following items: 
 1) a description of the documentation (including policies) reviewed and any personnel interviewed, and a list and description of the activities and efforts undertaken by Jazz to assist the IRO in connection with the
Systems Review; 
 2) a detailed description of Jazz’s systems, policies, processes, and practices with regard to the items identified in
Sections II.A.1-6 above, including a general description of Jazz’s control and accountability systems (e.g., documentation and approval requirements, tracking mechanisms) and written policies regarding the Reviewed Policies and
Practices; 
 3) a description of the manner in which the control and accountability systems and the written policies relating to the items
identified in Sections II.A.1-6 above are made known or disseminated within Jazz; 
 4) a detailed description of any system used to track and
respond to requests for information about Jazz’s products (e.g., through the Inquiries Database); 
 5) a detailed description of
Jazz’s compensation system (including salaries and bonuses) for non-Overtime Eligible employees, included a description of the bases upon which compensation is determined and the extent to which compensation is based on product performance. To
the extent that 

  

 5 
 Appendix B to CIA 
 Jazz Pharmaceuticals, Inc. 

 
Jazz may establish compensation differently for individual products, the IRO shall report separately on each such type of compensation arrangements;

 6) findings and supporting rationale regarding any weaknesses in Jazz’s systems, policies, processes, and practices relating to
Reviewed Policies and Practices, if any; and 
 7) recommendations to improve any of the systems, policies, processes, or practices relating
to the Reviewed Policies and Practices, if any. 
 Prior to the IRO’s submission of the report to the OIG, Jazz shall be provided with a
copy of the report and an opportunity to respond to each comment made by the IRO. Provided it does not delay the timely filing of the Annual Reports, any responses by Jazz may be included in the IRO report submitted to the OIG. Otherwise, any
responses by Jazz to the IRO’s findings may be submitted separately to the OIG following the Annual Report submission. 
  

	III.	Promotional and Product Services Transactions Review  

 The IRO shall conduct a Promotional and Product Services Transactions Review for each Reporting Period. As described below, each Transactions Review shall include a review of a sample of Inquiries reflected in the
Inquiries Database. 
  

	 	A.	Promotional and Product Services Transactions Review  

 As described in Section III.K of the CIA, Jazz has implemented a policy addressing the appropriate handling of requests for information about non-FDA approved uses of products (off-label information). Jazz documents
and records all Inquires (as defined in Section III.B.2.f) and the responses thereto in an Inquiries Database. The Inquiries Database shall include the items set forth in Section III.B.2.f for each Inquiry. On a monthly basis, reports of the
Inquiries are provided to the Compliance Officer and reviewed to determine whether improper promotion may have occurred in connection with one or more Inquires. If the Compliance Officer suspects that improper promotion may have occurred, the
Compliance Officer undertakes an Off-Label Review as described in Section III.K. 
 As part of the Promotional and Product
Services Transactions Review, the IRO shall evaluate Jazz’s processes relating to its Inquiries Database. Specifically, the IRO shall select a random sample of 25 Inquiries from among the Inquiries reflected in the Inquiries Database for each
Reporting Period. 
 For each Inquiry reviewed, the IRO shall determine: 
 i) whether each item of information listed in Section III.B.2.f of the CIA is reflected in the Inquiries Database for each reviewed Inquiry; and

  

 6 
 Appendix B to CIA 
 Jazz Pharmaceuticals, Inc. 

 ii) for each Inquiry for which the Compliance Officer conducted an Off-Label Review, the basis for
suspecting that improper off-label promotion may have occurred; the steps undertaken as part of the Off-Label Review; the findings of the Compliance Officer as a result of the Off-Label Review; and any follow-up actions taken by Jazz based on the
Compliance Officer’s findings. 
 B. Promotional and Product Services Transactions Review Report 
 The IRO shall prepare a report which shall include the following: 
 1. Elements to be Included: 
 a. Promotional and Product Services Transactions Review Objectives: A clear statement of the
objectives intended to be achieved by the Review; 
 b. Engagement Protocol: A detailed narrative description of the procedures performed and
a description of the universe of Inquiries from which the samples were selected; and 
 c. Sources of Data: A full description of the
documentation (and/or other information) relied upon by the IRO when performing the Promotional and Product Services Transactions Review. 
 2. Results to Be Included: 
 The following results shall be included in each Promotional and Product Services Transactions
Review Report: 
 a. a description of each type of sample unit reviewed, including the number of each type of sample reviewed (i.e.,
the number of Inquiries) and an identification of the types of documents and information reviewed for the Inquiries; 
 b. for each
Inquiry sample unit, the IRO shall summarize the information contained in the Inquiries Database about the Inquiry; 
 c. for each Inquiry
sample unit, the IRO shall state its findings and supporting rational as to whether: (i) each element listed in Section III.B.2.f of the CIA is reflected in the Inquiries Database for each 

  

 7 
 Appendix B to CIA 
 Jazz Pharmaceuticals, Inc. 

 
reviewed Inquiry; (ii) for each Inquiry for which the Compliance Officer conducted an Off-Label Review, the basis for suspecting that improper off-label
promotion may have occurred; the steps undertaken as part of the Off-Label Review; the findings of the Compliance Officer as a result of the Off-Label Review; and any follow-up actions taken by Jazz as a result of the Compliance Officer’s
findings; 
 d. the findings and supporting rationale regarding any weaknesses in Jazz’s systems, processes, policies, and practices
relating to the Inquiries, if any; and 
 e. recommendations for improvement in Jazz’s systems, processes, policies, and practices
relating to the Inquires, if any. 
 Prior to the IRO’s submission of the report to the OIG, Jazz shall be provided with a copy of the
report and an opportunity to respond to each comment made by the IRO. Provided it does not delay the timely filing of the Annual Reports, any responses by Jazz may be included in the IRO report submitted to the OIG. Otherwise, any responses by Jazz
to the IRO’s findings may be submitted separately to the OIG following the Annual Report submission. 
  

 8 
 Appendix B to CIA 
 Jazz Pharmaceuticals, Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}]]